About us

Panacea Venture is a healthcare venture fund with global vision and reach

Our firm

Dedicated to following promising innovation and building successful companies to transform lives

Our team

We are an accomplished team of creative thinkers, collaborators, connectors and along with our partners are building tomorrow’s breakthroughs together

Our strategy

Our forward-looking and adaptive investment strategy foresees and anticipates industry and policy trends, adjusting accordingly to optimize our competitive advantage

Our firm

Spun out from Kleiner Perkins China, the founding partners set up a new platform to leverage the sea change occurring in China, while establishing a global footprint to invest in innovation.

To date, Panacea Venture has raised three USD funds and an RMB fund from renowned institutional funds as well as strategic investors and has investments in more than 30 private companies and several public companies.

Our team

Panacea is comprised of 19 Partners, Venture Partners and advisors. The team sits in 3 continents and represent a diverse skill base ranging from entrepreneur to industry function expertise which includes clinical development, regulatory, commercial analysis and business development.

Our highly experienced investment Partners have greater than 100 years of investing experience combined, and along with our Venture Partners and advisors have collective experience in emerging and established biotech/diagnostic/medtech, global MNC companies, and key regulatory agencies such as FDA.

outline of a world map
Shanghai
Boston
Silicon Valley

Our strategy

We specialize in building innovative and transformative early and growth stage healthcare and life science companies globally while leveraging key elements of our original China presence.

Our forward-looking and adaptive investment strategy foresees and anticipates industry and policy trends, adjusting accordingly in order to optimize our competitive advantage.

We invest across the sub-sectors of life sciences, across geography and development stage, while leveraging our unique cross functional talent base to create value from company formation all the way to public market investing.